Suppr超能文献

房颤患者的药物使用与结局的时间趋势。

Temporal trends in medication use and outcomes in atrial fibrillation.

机构信息

Division of General Internal Medicine, McGill University Health Centre, Montreal, Québec, Canada; Division of Clinical Epidemiology, McGill University Health Centre, Montreal, Québec, Canada.

出版信息

Can J Cardiol. 2013 Oct;29(10):1241-8. doi: 10.1016/j.cjca.2012.09.021. Epub 2013 Jan 8.

Abstract

BACKGROUND

Novel therapies for anticoagulation and rhythm control for atrial fibrillation (AF) have been developed recently. To best evaluate the comparative effectiveness of newer agents, practice patterns and outcomes of existing therapies must be characterized at the population level.

METHODS

We conducted a retrospective population-based cohort study of patients ≥ 65 years with a first diagnosis of AF over a 9-year period in Québec and Ontario. Using hospital and drug claims databases, trends of filled prescriptions, and rates of strokes, bleeding complications, and mortality within 1 year were estimated.

RESULTS

From 1998 to 2006, 338, 479 patients were hospitalized with an AF diagnosis. Median age was 77.5 years and 50.4% were male. Use of rate control was 3-fold higher than rhythm control therapy. There was a modest decrease in rate control therapy until 2001 (71.9% to 70.6%, P = 0.01), followed by a progressive increase (70.6% to 76.4%, P = 0.014). An opposite trend was observed for rhythm control. Although warfarin prescriptions increased (51.0% to 64.5%, P < 0.0001), stroke rates tended to decrease (3.8% to 3.5%, P = 0.148). Bleeding complications increased mostly because of emergency room visits (4.8% to 6.1%, P = 0.007). Mortality remained high despite a small but statistically significant decline (27.6% to 25.8%, P = 0.018).

CONCLUSIONS

With increased anticoagulation use, stroke rates are declining and emergency room bleeding complications are increasing. Despite an increased use of evidence-based AF therapies, mortality remains high in this population. These findings highlight the need to focus on AF prevention in addition to minimizing its complications.

摘要

背景

最近已经开发出了用于抗凝和房颤(AF)节律控制的新型疗法。为了最好地评估新型药物的比较效果,必须在人群水平上描述现有疗法的实践模式和结果。

方法

我们进行了一项回顾性的基于人群的队列研究,研究对象是在魁北克省和安大略省的 9 年内首次诊断出患有 AF 的年龄≥65 岁的患者。我们使用医院和药物索赔数据库,估计了 1 年内的处方填充率、中风、出血并发症和死亡率。

结果

1998 年至 2006 年间,有 338,479 名患者因 AF 住院。中位年龄为 77.5 岁,50.4%为男性。与节律控制治疗相比,心率控制的使用率高 3 倍。直到 2001 年,心率控制治疗的使用率才略有下降(从 71.9%降至 70.6%,P=0.01),随后逐渐增加(从 70.6%增至 76.4%,P=0.014)。相反,节律控制的趋势是下降的。尽管华法林的处方量增加(从 51.0%增至 64.5%,P<0.0001),但中风的发生率却呈下降趋势(从 3.8%降至 3.5%,P=0.148)。出血并发症的增加主要是由于急诊就诊(从 4.8%增至 6.1%,P=0.007)。尽管死亡率略有下降(从 27.6%降至 25.8%,P=0.018),但仍居高不下。

结论

尽管增加了抗凝药物的使用,但中风的发生率正在下降,急诊出血并发症的发生率正在上升。尽管人群中使用了更多基于证据的 AF 治疗方法,但死亡率仍然很高。这些发现强调了除了尽量减少并发症外,还需要关注 AF 的预防。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验